缇乐®（注射用维替索妥尤单抗）获国家药品监督管理局批准用于治疗复发或转移性宫颈癌成人患者 Read more about 缇乐®（注射用维替索妥尤单抗）获国家药品监督管理局批准用于治疗复发或转移性宫颈癌成人患者
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026 Read more about argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy Read more about Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA nephropathy
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - SC Read more about Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - SC
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG Read more about argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates - SC Read more about Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates - SC
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - SC Read more about Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - SC
再鼎医药公布新临床前数据 显示IL-13/IL-31Rα双特异性抗体ZL-1503在特应性疾病中可快速缓解瘙痒并减轻炎症 Read more about 再鼎医药公布新临床前数据 显示IL-13/IL-31Rα双特异性抗体ZL-1503在特应性疾病中可快速缓解瘙痒并减轻炎症